Redeye returns with an updated view following Elicera’s Q1 report and encouraging data from the phase I/II CARMA study, evaluating ELC-301 in diffuse large B-cell lymphoma (DLBCL). Based on the positive clinical signals, we have raised our assumptions related to the likelihood of approval and potential deal terms for ELC-301. In addition, we have lowered the WACC in accordance with Redeye’s revised rating model. These changes result in a higher valuation range.
LÄS MER
